drugset / Trial / NCT00648791

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

NCT00648791

Phase 1 Completed 29 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's finasteride 5 mg tablets to Merck's Proscar® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administration under fasting conditions.

Timeline

Start
2004-09
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Finasteride Small molecule 5 mg Oral

Indications

No indication recorded.